Sumitomo Chemical Company, Limited

Sumitomo Pharmaceuticals Company Limited

Yamanouchi Pharmaceutical Company Ltd.

Yoshiya Yamahira

Keiji Fujioka

Shigeji Sato

Yoshihiro Takada

Tetsuo Noguchi

Yoshiko Okuzawa

Tadao Maeda

Takeshi Noguchi

Yoshihiro Komuro

Seiko Miura

Toshio Nakamura

Shiegeji Sato

Reimei Ishikawa

Terutsugu Tsuji

Hiroshi Takenaka

Kaoru Yamamori

Chikako Matsusaka

Katsuhiko Shima

The present invention relates to a sustained-release injection, which comprises a suspension of a powder comprising an active ingredient and a pharmaceutically acceptable biodegradable carrier (e.g. proteins, polysaccharides and synthetic high molecular compounds, preferably collagen, atelocollagen, gelatin, and a mixture thereof) in a viscous solvent for injection (e.g. vegetable oils, polyethylene glycol, propylene glycol, silicone oil, and medium-chain fatty acid triglycerides). The sustained-release injection can release the active ingredient at an effective level for a long period of time when injected.

Sustained-release injection

A sustained-release preparation of indomethacin or interferon comprising the active ingredient in admixture with a pharmaceutically acceptable biodegradable carrier, particularly a carrier selected from collagen, gelatin, and a mixture thereof. Said preparation is particularly suitable for parenteral administration and can release the active ingredient in an effective amount for a long period of time.

Sustained-release preparation

A solid sustained-release preparation in the form of a needle-like or bar-like shape, which consists essentially of an active ingredient and a pharmaceutically acceptable biodegradable carrier (e.g. proteins, preferably collagen, gelatin, and a mixture thereof). The sustained release preparation can be administered to the body or implanted into the body by injection or an injection-like method and can release the active ingredient at an effective level for a long period of time when administered.

Long-term sustained-release preparation

An antimicrobial preparation of D-7-[.alpha.-(4-hydrooxy-6-methylnicotinamido)-4-hydroxyphenylacetamido]-3 -(1-methyltetrazol-5-yl)thiomethyl-.DELTA..sup.3 -cephem-4-sodium carboxylate (hereinafter referred to as 'Compound A' of enhanced stability is disclosed, which comprises a microbially effective amount of Compund A and a stabilizer selected from the class consisting of benzoic acid, sodium benzoate and nicotinamide.

Antimicrobial preparation

A sustained-release preparation of indomethacin or interferon comprising the active ingredient in admixture with a pharmaceutically acceptable biodegradable carrier, particularly a carrier selected from collagen, gelatin, and a mixture thereof. The preparation is particularly suitable for parenteral administration and can release the active ingredient in an effective amount for a long period of time.

A solid sustained-release preparation in the form of a needle-like or bar-like shape, which consists essentially of an active ingredient and a pharmaceutically acceptable biodegradable carrier (e.g. proteins, preferably collagen, gelatin, and a mixture thereof). The sustained-release preparation can be administered to the body or implanted into the body by injection or an injection-like method and can release the active ingredient at an effective level for a long period of time when administered.

A pharmaceutical composition is provided herein containing as a key ingredient 4-carbamoyl-imidazolium-5-oleate of the formula (I) ##STR1## its salt or hydrate thereof, and one or more of a sulfur compound capable of producing at least one of the ions selected from HSO.sub.3.sup.--, SO.sub.3.sup.2-- and S.sub.2 O.sub.5.sup.2--. The sulfur compounds prevent discoloration of the composition. The stabilization against coloration is further enhanced by the presence of L-cysteine hydrochloride. The solubility of the compound (I) can be further enhanced by the presence of a basic substance. The active ingredient is known as a therapeutic agent for the treatment of such diseases as rheumatism and nephritis.

Pharmaceutical composition for injection

An antiinflammatory cream preparation which comprises an antiinflammatory substance hardly soluble in water in a base composition at a concentration of 0.05 to 1.5% by weight based on the preparation, the base composition comprising a medium chain fatty acid triglyceride of which the fatty acid has 6 to 12 carbon atoms, carboxyvinyl polymer and purified water in a weight proportion of 1-25:0.3-3:75-99, and with an adjusted pH of 4 to 10. The cream preparation is excellent in the availability of the antiinflammatory substance contained therein and advantageously is low in stimulation and high in safety.

Cream Preparation

Method for the treatment of glaucoma or ocular hypertension by topically applying to the eye an effective amount of 2-(3-tert.-butylamino-2-hydroxypropylthio)-4-(5-carbamoyl-2-thienyl)-thiaz ole or its acid addition salt to lower the intraocular pressure of the diseased eye.

Treatment of glaucoma or ocular hypertension and ophthalmic composition

A composition comprising as the pharmaceutically active ingredient bencyclane fumarate and cyclodextrin. As compared with prior bencyclane fumarate preparations, this composition can greatly decrease the adverse effects of bencyclane fumarate and, in addition, offers considerable advantages from the viewpoints of method of use and method of production of preparation.

Pharmaceutical composition comprising bencyclane fumarate and

A method for preparing a stable urokinase injection by the liophilization of urokinase which comprises liophilizing an aqueous solution containing urokinase, human serum albumin and one or more amino acid compounds selected from polar amino acids and salt thereof. The urokinase injection obtained according to this method is excellent in the storing stability as compared with conventional urokinase preparations for injection.

Method for preparing urokinase injection

A process for freeze-drying a penicillin derivative of the formula: ##STR1## wherein R is a hydrogen atom or a hydroxyl group, by evaporating a frozen aqueous solution of the penicillin derivative (I) under vacuum from the frozen state to dryness, which is characterized by maintaining the temperature of the frozen solution within a range from the eutectic point of the solution determined by the electric resistance method to -8.degree. C. when the penicillin derivative of the formula (I) wherein R is a hydrogen atom is to be freeze-dried, or -10.degree. C. when the penicillin derivative of the formula (I) wherein R is a hydroxyl group is to be freeze-dried during the primary drying period of the drying process.

Process for preparing a solid preparation of a penicillin derivative

Pharmaceutical compositions with controlled rates of gastro-intestinal absorption are prepared by dissolution or suspension of the therapeutically active agent in an absorption depressive agent selected from the group consisting of unsaturated aliphatic alcohols or their esters, unsaturated aliphatic ethers, unsaturated aliphatic acids or their salts, their esters or their amides and natural occurring oils containing more than 35% by weight of any of the above-mentioned substances, said absorption depressive materials having 12 - 22 carbon atoms in their unsaturated aliphatic hydrocarbon chains and being liquid at the normal temperature.

Growing community of inventors

Kobe, Japan

Yoshiya Yamahira